Articles tagged with Alzheimer Disease
Researchers identified mechanisms in Alzheimer's disease that cause neurons to de-differentiate and lose synaptic connections, resulting in cognitive decline. The study found changes in chromatin structure trigger these effects.
A University of Missouri researcher has developed procedures to define the preclinical stages of Alzheimer's disease, which can help drug developers identify potential beneficiaries of a future treatment. The study found that 42% of individuals with Alzheimer's-related brain pathology showed no signs of cognitive decline.
A new study analyzing cognitive decline in diverse Latinx populations found that the APOE-ε4 gene variant is associated with increased risk of cognitive decline. Interestingly, a higher proportion of genetic Amerindian ancestry was found to protect against this risk.
A three-year study published in 'Alzheimer's & Dementia' shows that a multinutrient formulation can significantly slow the deterioration of cognitive performance and brain atrophy in early Alzheimer's patients. Patients who received the nutrient drink suffered between 40-70% less cognitive impairment than those in the control group.
Researchers at HKUST have identified novel molecular targets for Alzheimer's drug development, focusing on endothelial cells and microglia. The study reveals a link between blood vessel dysregulation and AD pathogenesis, as well as potential therapeutic interventions through the cytokine IL-33.
A new treatment method increases the body's own degradation of protein building blocks, reducing all types of aggregates. The method uses somatostatin fused to a brain transport protein, allowing it to enter the brain and target the smallest, most toxic aggregates.
A novel class of compounds called rhizolutin has been discovered in a soil bacterium, Rhizolutin dissociates protein aggregates associated with Alzheimer's disease both in vivo and in vitro. The compound has been shown to reduce inflammatory processes and cell death caused by Aβ plaques in neuronal and glial cells.
Researchers develop a new PET-based imaging technique to detect abnormal tau protein deposits in the brain, which can diagnose Alzheimer's disease and frontotemporal lobar degeneration disorders with high accuracy. The method has shown promising results in detecting tau aggregates in patients with various forms of dementia.
A machine-learning algorithm detects early stages of Alzheimer's disease using functional magnetic resonance imaging (fMRI). The algorithm uses a convolutional neural network (CNN) to analyze fMRI data and classify patients as healthy, mild cognitive impairment, or Alzheimer's disease.
Researchers found that individuals with lower sustained attention ability and those who engage in heavy media multitasking perform worse on memory tasks. By monitoring pupil size and brain activity, scientists can predict whether an individual will remember or forget.
Scientists developed a new epigenetic clock specifically for the human brain, which is more accurate than previous models. The clock predicts biological age from DNA samples and may help understand accelerated ageing in the brain, potentially associated with brain diseases like Alzheimer's disease.
Researchers will present on anti-amyloid treatments and new late-stage clinical trials for Alzheimer's. NIA is funding over 230 active clinical trials to support the development of new treatments.
A study by Tokyo Metropolitan University reveals that a specific MARK4 mutation causes tau protein to aggregate in the brain, leading to Alzheimer's disease. The mutated enzyme makes tau proteins sticky and insoluble, causing neurons to die and memory functions to impair.
Researchers found that rural individuals with Alzheimer's disease had lower healthcare use and shorter survival rates compared to urban counterparts. The study also highlighted disparities in care access, highlighting the need for targeted interventions to address these gaps.
A multi-institutional team led by UCI researchers will expand research on biomarkers of Alzheimer's disease in adults with Down syndrome. The five-year, $109M grant aims to improve the quality of life of aging individuals with Down syndrome through advancing prevention and treatment strategies.
Washington State University scientists developed a method to detect Alzheimer's disease biomarkers in blood, 10 times more sensitive than current technology. The artificial enzyme, called a nanozyme, can detect the biomarkers at levels lower than commercial ELISA tests.
A preclinical study suggests a novel therapeutic immunomodulatory vaccine may slow memory impairment and prevent Aβ oligomer aggregation, with strong immunomodulatory effects without inducing inflammation. The vaccine targets toxic Aβ molecules in the brain, providing a safer alternative to existing anti-amyloid treatments.
A large-scale study found significant associations between air pollution and an increased risk of hospital admissions for several neurological disorders. The research analyzed data from over 63 million US adults and linked fine particulate pollution with higher rates of Parkinson's disease, Alzheimer's disease, and other dementias.
Researchers have discovered a neuroprotective treatment that can reverse cognitive impairment caused by chronic traumatic brain injury. The brief pharmacologic treatment, known as P7C3-A20, restored normal cognitive function in mice and stopped chronic neurodegeneration.
Researchers are using artificial intelligence to integrate and analyze genetic, imaging, and clinical data from over 60,000 Alzheimer's patients. This project aims to identify precise diagnostic biomarkers and drug targets for the disease, which affects nearly 50 million people worldwide.
Researchers at the University of South Florida Health found that SSH1 disrupts p62's ability to clear damaged tau proteins and mitochondria, leading to accumulation of toxic cellular waste. This defect may help develop SSH1 inhibitors to treat neurodegenerative diseases.
Research reveals a correlation between impaired blood flow and tau protein buildup in Alzheimer's disease, suggesting targeting vascular function as a key to prevention and treatment. The study used MRI and PET scans to compare blood flow and tau levels in older adults with varying degrees of cognitive impairment.
Researchers investigated exposure to general anesthesia versus regional anesthesia in elective surgery and found no long-term link to dementia. The Journal of the American Geriatrics Society study followed 7,499 individuals aged 66+ for up to 5 years.
A $2.7M NIH grant will fund a research program investigating the relationship between loneliness and brain structure/function in typically aging people and those at risk for Alzheimer's disease. The project aims to advance understanding of how social isolation impacts brain aging and progression to AD.
Faculty members Peter Adams and Jerold Chun receive prestigious awards for groundbreaking research on human aging and Alzheimer's disease. The grants will support innovative approaches to healthy aging, prevent degenerative disease and cancer.
A new study reveals that the APOE4 variant of the APOE gene disrupts a key process in brain cells, while increasing PICALM expression can repair the damage. The findings suggest that faulty endocytosis plays a crucial role in Alzheimer's disease etiology.
Researchers at UC Davis School of Medicine and UTHealth will study the role of incidental white matter lesions in dementia among diverse people with cognitive complaints. The team aims to develop a 'risk profile' that identifies the likelihood of WML-related cognitive impairment and dementia over five to 10 years.
Researchers aim to develop treatments that can prevent or treat Alzheimer's disease with two large-scale studies on pre-dementia conditions MCR and brain stimulation techniques.
A study by Universitat Autonoma de Barcelona found that social isolation exacerbates hyperactivity, anxiety, and asymmetric brain atrophy in mice with Alzheimer's disease. Isolation also affects fine motor skills and emotional patterns, highlighting the need for personalized interventions.
Researchers discovered a novel mutation in the VCP gene leading to a buildup of tau proteins and neuronal vacuoles, characteristic of Vacuolar Tauopathy (VT), a rare neurodegenerative disease. The study suggests a new therapeutic target for Alzheimer's disease by boosting VCP activity to break up protein aggregates.
A study of Latino caregivers found that poorer cognitive performance at a single testing point was associated with impairments in daily activities seven years later. The study suggests maintaining cognitive health in middle-age and older adulthood is crucial for independence.
A new study has confirmed the long-suspected link between sleep apnea and Alzheimer's disease, identifying identical signs of brain damage in both conditions. The research found amyloid plaques, a known indicator of Alzheimer's, in the brains of people with obstructive sleep apnea.
Penn researchers found that epigenetic changes disable protective pathways and enable pro-disease pathways in older brain cells with Alzheimer's Disease. These changes can be targeted by drugs, suggesting a new approach to treating early-stage disease.
Researchers are developing a novel deep learning technique to identify relationships between brain networks and Alzheimer's disease using algorithms mimicking neural networks. The goal is to pinpoint specific areas in the brain to slow and treat disease progression.
A new study found that the PLCG2-P522R genetic variant protects against Alzheimer's disease by enhancing immune cell functions, including phagocytic activity and immune response. The results highlight the importance of targeting this pathway for future therapy development.
Researchers will investigate cardiovascular risk factors on Alzheimer's pathology and examine effects of hypertension, homocysteine, and other biomarkers on cognitive decline. The project aims to identify preventative strategies for Alzheimer's disease by maintaining cardiovascular health.
Researchers at Center for BrainHealth used 7-Tesla MRS to differentiate energy molecules in the brains of patients with amnestic mild cognitive impairment, a condition that may lead to Alzheimer's disease. The findings could help develop tests for early detection and treatment of Alzheimer's.
A new pathway discovered by researchers at the University of Kentucky's Sanders-Brown Center on Aging has shown that eIF5A hypusination governs TDP-43 accumulation and aggregation. Pharmacological inhibition of an enzyme generating hypusinated eIF5A significantly reduced TDP-43 cytoplasmic accumulation and aggregation in cells.
A new study suggests that excessive fructose metabolism in the brain may be a key driver of Alzheimer's disease. The research proposes that high fructose levels disrupt cerebral metabolism and neuronal function, leading to progressive loss of energy and eventual neuronal death.
Researchers identified Neurofilament light chain in vitreous humor, a potential biomarker for Alzheimer's and Parkinson's diseases. Higher levels were associated with higher levels of other biomarkers known to be linked to neurodegeneration.
Researchers found that actively using two languages enhances cognitive reserve and delays the onset of symptoms associated with cognitive decline and dementia. The study suggests that bilingualism is an important predictor of delay in the onset of mild cognitive impairment, a preclinical phase of Alzheimer's disease.
Researchers at Massachusetts General Hospital have developed a molecular imaging probe to reveal γ-secretase related to Alzheimer's disease. The study aims to better understand the etiology of AD and facilitate drug discovery.
Dr. Joseph Arboleda-Velásquez will investigate genetic links to Alzheimer's resistance using a rare genetic variation that provided protection in a Colombian woman. The goal is to discover related drug and gene therapies for the devastating disease.
A genetic variation has been identified that may increase the risk of cognitive decline in some individuals, even those without amyloid plaques or tau tangles. The variation affects glutathione metabolism and is associated with thinning of the brain cortex.
A study of 82 young adults with varying ApoE gene variants found no differences in memory performance, but distinct brain activity patterns, suggesting potential early disease processes. The researchers used functional MRI to examine the impact on the hippocampus, an area crucial for memory.
Researchers found that older people without cognitive problems who experience a fall may have already begun neurodegeneration leading to Alzheimer's dementia. The study suggests that falls in this population are linked to brain changes that can be prevented with environmental modifications.
The University of North Texas Health Science Center has received a $45 million grant to study health disparities in Alzheimer's disease among multi-ethnic populations. The research aims to understand the biological framework of the disease in Mexican Americans, who develop Alzheimer's 10 years earlier than non-Latino whites.
The NIH has augmented the Health and Aging Brain Among Latino Elders (HABLE) Study to include additional biomarkers, including positron emission tomography (PET) imaging, to better understand Alzheimer's disease in Mexican Americans. The study will help identify health disparities and potential treatments for the condition.
A new program will continue dementia surveillance and invigorate the brain donation program using FHS participants' cognitive assessments and brain imaging. The program aims to identify genetic and biomarker factors related to Alzheimer's disease and develop strategies to preserve cognition.
The National Institute on Aging has funded four new exploratory Alzheimer's Disease Research Centers to broaden current research initiatives with underrepresented populations. These centers will prioritize rural communities and focus on specific scientific areas such as vascular risk factors and disparities in the Deep South region.
Even mild concussions can lead to severe and long-lasting impairments in the brain's ability to clean itself of toxins, potentially seeding Alzheimer's disease and dementia. The discovery sheds light on why repeated brain injuries are so harmful and suggests a reason for varying effects among individuals.
Researchers aim to determine how autophagy, a cellular recycling process, is related to Alzheimer's disease and dementia. They will examine the effect of compromised autophagy on peripheral tissues and explore potential interventions to reverse decline.
Researchers discovered a novel role of tau specific to FTLD spectrum diseases, contributing to conditions like ALS, PSP, and CBD, but not AD and Pick's disease. The study proposes an imbalanced accumulation of tau model, where FUS and SFPQ regulate MAPT processing, leading to increased 4-repeat tau levels.
A study published in Neurology found that anticholinergic drugs may accelerate cognitive decline in older adults, particularly those at risk for Alzheimer's disease. Researchers discovered that participants taking these medications were 47% more likely to develop mild cognitive impairment over a decade.
A University of Houston researcher is investigating the adverse effects of mixing cholinesterase inhibitors and antimuscarinics in patients with Alzheimer's disease. The study aims to evaluate drug interactions and their effects on severe adverse events, ultimately improving the quality of medication use in dementia care.
Researchers at UC Berkeley found a correlation between poor sleep quality and increased beta-amyloid plaques in the brain, indicating an earlier onset of Alzheimer's disease. Deep non-REM slow-wave sleep has been identified as a potential target for intervention against cognitive decline.
A recent MSK study discovered a direct link between inflammation and Alzheimer's disease development, highlighting the role of protein IFITM3 in plaque formation. Researchers found that removing IFITM3 reduced amyloid plaques in a mouse model, suggesting a potential biomarker for early detection.
A study found that taking at least one anticholinergic drug increases the risk of developing mild cognitive impairment by 47%, particularly in those with genetic risk factors for Alzheimer's disease. The study suggests reducing anticholinergic use may help prevent negative effects on thinking skills.
Researchers found that a Mediterranean ketogenic diet can alter specific gut fungi associated with higher Alzheimer's disease risk. The study suggests that this dietary approach may help reduce harmful fungi in the gut, potentially leading to improved mental health outcomes.
Researchers found that individuals with a genetic risk for Alzheimer's disease exhibit impaired path integration, a cognitive ability essential for spatial navigation. The study suggests that grid cell activity in the entorhinal cortex plays a crucial role in this process, and may serve as a potential biomarker for early diagnosis.